Therapeutics Initiative |

06 Feb [109] Inhaled long acting β2 agonists for COPD

Posted at 20:51h in Therapeutics Letter 0 Comments

In Therapeutics Letter #1021 we reviewed the inhaled long acting β2 agonist (LABA) indacaterol for chronic obstructive pulmonary disease (COPD). We concluded “There are no proven clinically meaningful benefits in terms of reduction in mortality...

26 Jan [102] Indacaterol for chronic obstructive pulmonary disease

Posted at 14:18h in Therapeutics Letter 0 Comments

Chronic obstructive pulmonary disease (COPD) is an inflammatory condition characterized by irreversible airflow obstruction. It is caused by exposure to noxious particles or gases, with exposure to cigarette smoke the most common cause. Several classes...

indacaterol Tag

06 Feb [109] Inhaled long acting β2 agonists for COPD

26 Jan [102] Indacaterol for chronic obstructive pulmonary disease

Contact

Subscribe for Updates